According to UK antimicrobial stewardship principles, what is the primary purpose of documenting an 'indication' when prescribing antimicrobials in the 'Start Smart - Then Focus' toolkit?
Q112
A 35-year-old woman presents to her GP with a 3-day history of increasing pain, redness, and swelling around her thumbnail. She works as a dental hygienist and reports frequent exposure to water. On examination, there is erythema and swelling of the nail fold with absence of the cuticle. No pus is visible. What is the most appropriate initial management?
Q113
A 52-year-old woman with a BMI of 42 kg/m² undergoes emergency laparotomy for perforated diverticulitis with peritoneal contamination. She receives appropriate surgical prophylaxis with co-amoxiclav 1.2g at induction. Post-operatively, the surgical team plans to continue co-amoxiclav 1.2g three times daily for 5 days as 'therapeutic' antibiotics. As the antimicrobial stewardship pharmacist, which of the following represents the most evidence-based recommendation?
Q114
A hospital trust implements a quality improvement initiative where all patients started on broad-spectrum antibiotics (piperacillin-tazobactam, carbapenems, or quinolones) must have a documented review decision within 48 hours, selecting from: stop, step-down to narrow spectrum, continue, or escalate. Six months post-implementation, audits show 85% compliance with documentation, mean duration of broad-spectrum therapy decreased from 6.2 to 4.1 days, and C. difficile rates decreased by 18%. However, there is significant variation between specialties (compliance 95% in respiratory medicine vs 68% in general surgery). What is the most appropriate next step to optimize and sustain this intervention?
Q115
A 67-year-old man with type 2 diabetes and chronic kidney disease stage 4 (eGFR 24 mL/min/1.73m²) presents with cellulitis of the right leg. He weighs 95kg. Blood tests show creatinine 245 μmol/L (baseline 220 μmol/L) and CRP 156 mg/L. He has a documented severe penicillin allergy (previous anaphylaxis). According to current UK guidance, what is the most appropriate antibiotic regimen?
Q116
A 38-year-old man who returned from visiting relatives in rural India 3 weeks ago presents with a 5-day history of a painless ulcer on his right forearm. The ulcer has raised, violaceous borders and a necrotic base. He recalls being bitten by an insect during his trip. He is systemically well with no fever or lymphadenopathy. The lesion has not responded to 3 days of oral flucloxacillin. What is the most likely diagnosis?
Q117
A hospital antimicrobial stewardship team implements a new intervention requiring pharmacist-led review of all antimicrobial prescriptions within 72 hours of initiation. After 6 months, audit data shows a 22% reduction in defined daily doses of antibiotics and a 15% reduction in mean duration of therapy, with no increase in 30-day mortality or readmission rates. However, the intervention requires 1.5 full-time equivalent pharmacists and costs £120,000 annually. Which framework is most appropriate to evaluate the overall value of this intervention?
Q118
A 44-year-old woman presents with a painful swelling in her right axilla. She underwent wide local excision of breast cancer with sentinel lymph node biopsy 10 days ago. On examination, there is a 5cm fluctuant, tender swelling in the axilla with surrounding erythema extending 8cm from the wound. Her temperature is 38.1°C. Ultrasound confirms a 4cm fluid collection. What is the most appropriate management?
Q119
A 56-year-old woman with end-stage renal failure on peritoneal dialysis presents with fever, abdominal pain, and cloudy dialysate fluid. Peritoneal fluid analysis shows WCC 420 cells/μL (>50% neutrophils). Gram stain shows no organisms. Empirical therapy is started. After 48 hours, culture grows coagulase-negative staphylococci sensitive to all antibiotics tested. What is the most appropriate management?
Q120
A 72-year-old man with chronic obstructive pulmonary disease is admitted with an infective exacerbation and started on intravenous co-amoxiclav. On day 3 of admission, he develops watery diarrhoea (6 episodes in 24 hours). Clostridioides difficile toxin is positive. His temperature is 37.8°C, heart rate 88 bpm, and blood pressure 128/76 mmHg. Blood tests show WCC 13.2 × 10⁹/L and creatinine 98 μmol/L. What is the most appropriate management?
Common Infections UK Medical PG Practice Questions and MCQs
Question 111: According to UK antimicrobial stewardship principles, what is the primary purpose of documenting an 'indication' when prescribing antimicrobials in the 'Start Smart - Then Focus' toolkit?
A. To facilitate accurate billing and coding for hospital reimbursement
B. To enable antimicrobial stewardship teams to audit prescribing appropriateness and review decisions at 48-72 hours (Correct Answer)
C. To provide medico-legal protection for the prescribing clinician in case of adverse outcomes
D. To ensure compliance with Care Quality Commission inspection requirements
E. To allow pharmacists to substitute alternative antimicrobials based on local formulary availability
Explanation: ***To enable antimicrobial stewardship teams to audit prescribing appropriateness and review decisions at 48-72 hours***- Clear documentation of the **indication** is a core component of the **'Start Smart'** phase, ensuring all clinical staff understand the rationale for the initial treatment.- It is essential for the **'Then Focus'** phase, allowing for a structured review at **48-72 hours** to decide whether to stop, de-escalate, or switch the antimicrobial.*To facilitate accurate billing and coding for hospital reimbursement*- While documentation is used for clinical coding, the **'Start Smart - Then Focus'** toolkit is a clinical safety and effectiveness framework, not a financial tool.- UK hospital reimbursement via the **NHS** does not rely on antimicrobial indications in the same way as private insurance-based systems.*To provide medico-legal protection for the prescribing clinician in case of adverse outcomes*- Good documentation inherently provides a **medico-legal record**, but this is a secondary benefit rather than the primary stewardship objective.- Stewardship focuses on **patient outcomes** and reducing **antimicrobial resistance** rather than clinician liability protection.*To ensure compliance with Care Quality Commission inspection requirements*- The **Care Quality Commission (CQC)** does look for evidence of stewardship, but compliance is the result of good practice, not the primary clinical goal of the documentation.- Clinical documentation is intended to drive **patient safety** and effective treatment transitions at the bedside.*To allow pharmacists to substitute alternative antimicrobials based on local formulary availability*- Identifying the **indication** helps the pharmacist verify appropriateness, but they generally cannot substitute agents without a **local protocol** or clinician consultation.- The primary goal of recording the indication is to facilitate the **prescriber's review** of the treatment plan once more clinical data is available.
Question 112: A 35-year-old woman presents to her GP with a 3-day history of increasing pain, redness, and swelling around her thumbnail. She works as a dental hygienist and reports frequent exposure to water. On examination, there is erythema and swelling of the nail fold with absence of the cuticle. No pus is visible. What is the most appropriate initial management?
A. Oral flucloxacillin for 7 days
B. Topical antifungal cream with avoidance of moisture (Correct Answer)
C. Incision and drainage under local anaesthetic
D. Oral clarithromycin for 5 days
E. Oral metronidazole for 7 days
Explanation: ***Topical antifungal cream with avoidance of moisture***
- This patient's presentation of **erythema**, **swelling of the nail fold**, and **absence of the cuticle** due to frequent **water exposure** is classic for **chronic paronychia**.
- The absence of pus and the occupational risk factors strongly suggest a **Candida** infection as the primary driver, making a **topical antifungal** and keeping the area dry the appropriate first-line treatment.
*Oral flucloxacillin for 7 days*
- **Flucloxacillin** is typically indicated for **acute bacterial paronychia**, which presents with rapid onset, severe pain, and often a **purulent collection**.
- This patient's history and examination (no visible pus, chronic nature, water exposure) are more consistent with a fungal or irritant cause, not a primary bacterial infection requiring systemic antibiotics.
*Incision and drainage under local anaesthetic*
- **Incision and drainage** is the treatment of choice for **acute paronychia** when a visible **abscess** or **fluctuance** is present, indicating a collection of pus.
- In this clinical scenario, there is **no visible pus**, and the underlying pathology is inflammatory/fungal rather than a localized bacterial collection requiring surgical intervention.
*Oral clarithromycin for 5 days*
- **Clarithromycin** is a macrolide antibiotic used for bacterial infections, often as an alternative for patients with **penicillin allergies**.
- It does not address the likely **fungal etiology** of chronic paronychia and is not indicated as a primary treatment for nail fold inflammation without clear evidence of bacterial cellulitis.
*Oral metronidazole for 7 days*
- **Metronidazole** is primarily effective against **anaerobic bacteria** and certain parasites.
- These are not the typical pathogens involved in chronic paronychia, which is commonly caused by **Candida species** or persistent irritation from **moisture exposure**.
Question 113: A 52-year-old woman with a BMI of 42 kg/m² undergoes emergency laparotomy for perforated diverticulitis with peritoneal contamination. She receives appropriate surgical prophylaxis with co-amoxiclav 1.2g at induction. Post-operatively, the surgical team plans to continue co-amoxiclav 1.2g three times daily for 5 days as 'therapeutic' antibiotics. As the antimicrobial stewardship pharmacist, which of the following represents the most evidence-based recommendation?
A. Support continuation of co-amoxiclav 1.2g three times daily for 5 days as this represents appropriate treatment for intra-abdominal infection
B. Recommend increasing to co-amoxiclav 2.4g three times daily due to obesity and severity of infection, continuing for 7 days
C. Recommend stopping antibiotics at 24 hours if source control achieved and no evidence of ongoing infection, as this is adequate for Hinchey grade III diverticulitis with successful source control (Correct Answer)
D. Recommend changing to piperacillin-tazobactam for broader coverage and continuing for minimum 5 days post-operatively
E. Recommend continuing antibiotics until inflammatory markers normalize (typically 7-10 days)
Explanation: ***Recommend stopping antibiotics at 24 hours if source control achieved and no evidence of ongoing infection, as this is adequate for Hinchey grade III diverticulitis with successful source control***
- Evidence from the **STOP-IT trial** and modern guidelines suggest that when **source control** (e.g., resection and washout) is successful, prolonged antibiotic courses do not improve outcomes.
- For cases of **peritoneal contamination** (Hinchey III), antibiotics function more as extended prophylaxis; continuing them for only **24 hours** post-operatively is safe and reduces the risk of resistance and side effects like *C. difficile*.
*Support continuation of co-amoxiclav 1.2g three times daily for 5 days as this represents appropriate treatment for intra-abdominal infection*
- Traditional **5-day courses** are increasingly considered unnecessary for intra-abdominal infections where the source of contamination has been surgically removed.
- This approach overlooks **antimicrobial stewardship** principles that prioritize minimizing exposure once the clinical focus of infection is eliminated.
*Recommend increasing to co-amoxiclav 2.4g three times daily due to obesity and severity of infection, continuing for 7 days*
- While **obesity** affects drug distribution, there is no clinical evidence that doubling the standard dose to 2.4g improves outcomes in this surgical context.
- A **7-day duration** is excessively long for a patient with achieved source control and increases the risk of **drug-induced toxicity** and healthcare-associated infections.
*Recommend changing to piperacillin-tazobactam for broader coverage and continuing for minimum 5 days post-operatively*
- **Piperacillin-tazobactam** provides broader anti-pseudomonal coverage which is generally not required for community-acquired **perforated diverticulitis** unless the patient is at high risk for resistant organisms.
- Escalating to a broader spectrum without clinical or **microbiological justification** violates core stewardship goals and promotes the selection of multi-drug resistant pathogens.
*Recommend continuing antibiotics until inflammatory markers normalize (typically 7-10 days)*
- **Inflammatory markers** like CRP often remain elevated for several days due to the trauma of **emergency laparotomy**, making them an unreliable sole indicator for stopping antibiotics.
- Relying on these markers leads to inappropriately **prolonged antibiotic therapy**, which does not correlate with a reduced rate of surgical site infections or abscess formation.
Question 114: A hospital trust implements a quality improvement initiative where all patients started on broad-spectrum antibiotics (piperacillin-tazobactam, carbapenems, or quinolones) must have a documented review decision within 48 hours, selecting from: stop, step-down to narrow spectrum, continue, or escalate. Six months post-implementation, audits show 85% compliance with documentation, mean duration of broad-spectrum therapy decreased from 6.2 to 4.1 days, and C. difficile rates decreased by 18%. However, there is significant variation between specialties (compliance 95% in respiratory medicine vs 68% in general surgery). What is the most appropriate next step to optimize and sustain this intervention?
A. Replace the intervention with automatic antibiotic stop orders at 48 hours across all specialties
B. Mandate immediate discontinuation of broad-spectrum antibiotics in surgery if review not documented within 48 hours
C. Conduct targeted education sessions with surgical teams, identify barriers to compliance, and implement specialty-specific solutions with ongoing feedback (Correct Answer)
D. Remove access to broad-spectrum antibiotics for surgical teams until compliance improves to 90%
E. Introduce financial penalties for consultants whose teams have <80% compliance with review documentation
Explanation: ***Conduct targeted education sessions with surgical teams, identify barriers to compliance, and implement specialty-specific solutions with ongoing feedback***
- Successful **antimicrobial stewardship** requires identifying specific **barriers to compliance** (e.g., surgical workflow or theatre time) and using **audit and feedback** to drive behavioral change.
- Tailoring interventions to specific clinical contexts through **stakeholder engagement** is more sustainable and effective than imposing rigid, top-down mandates.
*Replace the intervention with automatic antibiotic stop orders at 48 hours across all specialties*
- **Automatic stop orders** can be clinically dangerous as they may interrupt treatment for patients with legitimate needs for continued **broad-spectrum therapy**.
- This approach removes **clinical judgment** and does not address the underlying reasons for poor documentation compliance.
*Mandate immediate discontinuation of broad-spectrum antibiotics in surgery if review not documented within 48 hours*
- This is a **punitive measure** that risks **patient safety** by potentially stopping necessary treatment for severe surgical infections.
- It fails to foster a **safety culture** and instead creates friction between the stewardship team and surgical staff.
*Remove access to broad-spectrum antibiotics for surgical teams until compliance improves to 90%*
- Restricting access to essential medicines like **carbapenems** or **piperacillin-tazobactam** prevents clinicians from treating life-threatening conditions like **sepsis**.
- This strategy is counterproductive and damages the **collaborative relationship** essential for effective hospital-wide quality improvement.
*Introduce financial penalties for consultants whose teams have <80% compliance with review documentation*
- **Financial penalties** focuses on punishment rather than **process improvement**, often leading to "gaming the system" or inaccurate documentation just to meet targets.
- Sustainable **quality improvement (QI)** relies on intrinsic motivation and demonstrating clinical benefits, such as the observed reduction in **C. difficile rates**.
Question 115: A 67-year-old man with type 2 diabetes and chronic kidney disease stage 4 (eGFR 24 mL/min/1.73m²) presents with cellulitis of the right leg. He weighs 95kg. Blood tests show creatinine 245 μmol/L (baseline 220 μmol/L) and CRP 156 mg/L. He has a documented severe penicillin allergy (previous anaphylaxis). According to current UK guidance, what is the most appropriate antibiotic regimen?
A. Intravenous clarithromycin 500mg twice daily
B. Intravenous teicoplanin loading dose 800mg, then 400mg once daily (Correct Answer)
C. Intravenous vancomycin 1g twice daily
D. Oral doxycycline 200mg loading dose, then 100mg twice daily
E. Intravenous clindamycin 600mg four times daily
Explanation: ***Intravenous teicoplanin loading dose 800mg, then 400mg once daily***
- In patients with **severe penicillin allergy** (anaphylaxis) requiring IV therapy, **teicoplanin** is preferred over vancomycin due to lower nephrotoxicity risk and simpler dosing in **stage 4 CKD**.
- A loading dose of **800-1200mg** (based on weight) followed by a reduced maintenance dose is appropriate to ensure rapid therapeutic levels while preventing accumulation in **renal impairment**.
*Intravenous clarithromycin 500mg twice daily*
- Macrolides like clarithromycin have **poor coverage** against certain strains of **Staphylococcus aureus**, which is a primary pathogen in cellulitis.
- It is generally not the first-line choice for severe cellulitis requiring hospitalization and IV therapy in a complex patient.
*Intravenous vancomycin 1g twice daily*
- Vancomycin carries a significant risk of **nephrotoxicity**, which is a major concern in a patient with a baseline **eGFR of 24 mL/min/1.73m²**.
- The dosing frequency (twice daily) would be excessive for this level of renal function and would require intensive **therapeutic drug monitoring (TDM)**.
*Oral doxycycline 200mg loading dose, then 100mg twice daily*
- **Oral therapy** is inappropriate in this scenario given the patient's age, comorbidities (Diabetes, CKD), and high **CRP (156 mg/L)** suggesting severe infection.
- Doxycycline is typically reserved for **mild cellulitis** managed in the outpatient setting for patients with penicillin allergies.
*Intravenous clindamycin 600mg four times daily*
- While effective against Gram-positive cocci, clindamycin is associated with a high risk of **Clostridioides difficile-associated diarrhea**, especially in elderly patients.
- High-dose frequent administration is less practical compared to the **once-daily maintenance** regimen provided by glycopeptides like teicoplanin.
Question 116: A 38-year-old man who returned from visiting relatives in rural India 3 weeks ago presents with a 5-day history of a painless ulcer on his right forearm. The ulcer has raised, violaceous borders and a necrotic base. He recalls being bitten by an insect during his trip. He is systemically well with no fever or lymphadenopathy. The lesion has not responded to 3 days of oral flucloxacillin. What is the most likely diagnosis?
A. Cutaneous leishmaniasis (Correct Answer)
B. Mycobacterium ulcerans infection (Buruli ulcer)
C. Cutaneous anthrax
D. Ecthyma gangrenosum
E. Chromoblastomycosis
Explanation: ***Cutaneous leishmaniasis***- This diagnosis is strongly suggested by the patient's travel to **rural India**, the history of a **sandfly bite**, and the development of a **painless ulcer** with **violaceous borders**.- The **incubation period** of several weeks and the lack of response to standard antibiotics like **flucloxacillin** are characteristic of this parasitic infection caused by **Leishmania species**.*Mycobacterium ulcerans infection (Buruli ulcer)*- While it causes painless ulcers, it is typically characterized by **undermined borders** rather than raised violaceous ones and is not common in **India**.- It progresses more slowly than cutaneous leishmaniasis and often presents initially as a **subcutaneous nodule**.*Cutaneous anthrax*- Although it presents as a painless lesion, it usually features a characteristic **black eschar** surrounded by extensive **perilesional edema**.- The progression is much more rapid (days) and is typically associated with **livestock exposure** rather than an insect bite.*Ecthyma gangrenosum*- This is a cutaneous manifestation of **Pseudomonas aeruginosa bacteremia** and occurs almost exclusively in **immunocompromised patients**.- It is associated with severe **systemic toxicity** and rapid progression, which contrasts with this patient's systemically well status.*Chromoblastomycosis*- This is a **chronic fungal infection** that typically presents as slow-growing, **verrucous (warty) plaques** rather than an acute ulcerative lesion.- It has a much more prolonged course over **months to years** and usually involves traumatic inoculation from soil or vegetation in outdoor workers.
Question 117: A hospital antimicrobial stewardship team implements a new intervention requiring pharmacist-led review of all antimicrobial prescriptions within 72 hours of initiation. After 6 months, audit data shows a 22% reduction in defined daily doses of antibiotics and a 15% reduction in mean duration of therapy, with no increase in 30-day mortality or readmission rates. However, the intervention requires 1.5 full-time equivalent pharmacists and costs £120,000 annually. Which framework is most appropriate to evaluate the overall value of this intervention?
A. Structure-Process-Outcome model to assess quality of care delivery
B. Cost-effectiveness analysis comparing costs per quality-adjusted life year gained
C. Interrupted time-series analysis to demonstrate causal relationship with outcomes
D. Balanced scorecard approach incorporating clinical, economic, and process measures (Correct Answer)
E. Root cause analysis to identify factors contributing to antibiotic overuse
Explanation: ***Balanced scorecard approach incorporating clinical, economic, and process measures***
- A **balanced scorecard** integrates various performance perspectives, making it ideal for evaluating this intervention's **clinical outcomes** (reduced antibiotic use, no increased mortality), **process efficiency** (pharmacist review, duration of therapy), and **economic costs** (£120,000, 1.5 FTE).
- It allows for a holistic assessment of the **overall value** by considering both the financial investment and the multi-faceted benefits in antibiotic stewardship.
*Structure-Process-Outcome model to assess quality of care delivery*
- The **Donabedian model** focuses on assessing the quality of care through structure (resources), process (activities), and outcome (results).
- While relevant for quality, it does not explicitly provide a framework to integrate and weigh the **economic costs** against the benefits to determine overall
Question 118: A 44-year-old woman presents with a painful swelling in her right axilla. She underwent wide local excision of breast cancer with sentinel lymph node biopsy 10 days ago. On examination, there is a 5cm fluctuant, tender swelling in the axilla with surrounding erythema extending 8cm from the wound. Her temperature is 38.1°C. Ultrasound confirms a 4cm fluid collection. What is the most appropriate management?
A. Start oral flucloxacillin and arrange outpatient review in 48 hours
B. Aspirate the collection with needle and syringe, send fluid for culture, and start oral antibiotics
C. Perform incision and drainage, send pus for culture, and start intravenous antibiotics (Correct Answer)
D. Start intravenous co-amoxiclav and request CT chest to exclude necrotising infection
E. Refer urgently to breast surgery for wound exploration under general anaesthesia
Explanation: ***Perform incision and drainage, send pus for culture, and start intravenous antibiotics***- The patient presents with a post-operative **surgical site infection (SSI)** and a confirmed **abscess** (fluctuance, 4cm fluid on ultrasound), which mandates **source control** via drainage.- **Intravenous antibiotics** are indicated due to systemic symptoms (**fever**) and significant spreading **cellulitis** (8cm erythema) beyond the immediate wound site.*Start oral flucloxacillin and arrange outpatient review in 48 hours*- Oral antibiotics alone are insufficient for an **established abscess** because they cannot penetrate the collection effectively to achieve sterilization.- Outpatient management is inappropriate given the systemic features and the need for immediate **surgical intervention** to drain the pus.*Aspirate the collection with needle and syringe, send fluid for culture, and start oral antibiotics*- **Needle aspiration** has a high failure rate for a 4cm collection and is often insufficient to provide complete **drainage and decompression**.- Oral antibiotics are inadequate here as the presence of fever and extensive erythema suggests the need for **systemic IV therapy**.*Start intravenous co-amoxiclav and request CT chest to exclude necrotising infection*- A **CT chest** is not routinely required as the diagnosis of a superficial **post-surgical abscess** is clearly established by clinical exam and **ultrasound**.- While IV coverage is correct, the management must prioritize **mechanical drainage** (source control) over advanced imaging unless there is evidence of crepitus or rapid systemic collapse.*Refer urgently to breast surgery for wound exploration under general anaesthesia*- Most superficial axillary abscesses can be managed with **incision and drainage** at the bedside or in a procedure room under **local anesthesia**.- **General anesthesia** and formal wound exploration are typically reserved for deep-seated infections or when there is concern for **necrotizing fasciitis**.
Question 119: A 56-year-old woman with end-stage renal failure on peritoneal dialysis presents with fever, abdominal pain, and cloudy dialysate fluid. Peritoneal fluid analysis shows WCC 420 cells/μL (>50% neutrophils). Gram stain shows no organisms. Empirical therapy is started. After 48 hours, culture grows coagulase-negative staphylococci sensitive to all antibiotics tested. What is the most appropriate management?
A. Remove peritoneal dialysis catheter immediately and switch to haemodialysis
B. Continue antibiotics for 14 days and reassess catheter removal if not improving
C. Add rifampicin to current antibiotic regimen and continue for 21 days
D. Continue antibiotics for 14-21 days, maintain catheter if clinical improvement within 5 days (Correct Answer)
E. Switch to oral antibiotics and arrange outpatient follow-up in one week
Explanation: ***Continue antibiotics for 14-21 days, maintain catheter if clinical improvement within 5 days***- For **coagulase-negative staphylococci (CoNS)** peritonitis, the standard course is **14 days** of appropriate antibiotics, provided there is a prompt clinical response.- **Catheter retention** is the goal; removal is only necessary if the infection is **refractory** (no improvement after 5 days), relapsing, or caused by fungi/mycobacteria.*Remove peritoneal dialysis catheter immediately and switch to haemodialysis*- **Immediate catheter removal** is typically reserved for severe cases such as **fungal peritonitis**, **mycobacterial peritonitis**, or **peritonitis refractory to initial antibiotic therapy**.- For common bacterial peritonitis like CoNS, an initial attempt to treat with **antibiotics while preserving the catheter** is the preferred approach.*Continue antibiotics for 14 days and reassess catheter removal if not improving*- While 14 days is a correct duration for CoNS, this option lacks the specific **early reassessment** (within 3-5 days) for clinical response, which is crucial for decision-making regarding catheter salvage.- Guidelines emphasize monitoring for **clinical improvement** (e.g., clear effluent, resolution of pain/fever) within the first few days of therapy.*Add rifampicin to current antibiotic regimen and continue for 21 days*- **Rifampicin** is not a first-line agent for CoNS peritonitis and is generally considered for **refractory Staphylococcus aureus** infections or specific tunnel infections.- A **21-day course** is often longer than necessary for sensitive CoNS, which usually responds well to a **14-day** regimen.*Switch to oral antibiotics and arrange outpatient follow-up in one week*- **Peritoneal dialysis peritonitis** requires adequate drug concentrations in the peritoneal cavity, best achieved with **intraperitoneal (IP)** or intravenous antibiotics initially.- Switching to **oral antibiotics** too early or using them as sole therapy for active peritonitis carries a high risk of **treatment failure** and catheter loss.
Question 120: A 72-year-old man with chronic obstructive pulmonary disease is admitted with an infective exacerbation and started on intravenous co-amoxiclav. On day 3 of admission, he develops watery diarrhoea (6 episodes in 24 hours). Clostridioides difficile toxin is positive. His temperature is 37.8°C, heart rate 88 bpm, and blood pressure 128/76 mmHg. Blood tests show WCC 13.2 × 10⁹/L and creatinine 98 μmol/L. What is the most appropriate management?
A. Stop co-amoxiclav, start oral vancomycin 125mg four times daily for 10 days (Correct Answer)
B. Continue co-amoxiclav, add oral metronidazole 400mg three times daily for 10 days
C. Stop co-amoxiclav, start oral fidaxomicin 200mg twice daily for 10 days
D. Stop co-amoxiclav, start intravenous metronidazole 500mg three times daily for 10 days
E. Stop co-amoxiclav, start oral vancomycin 500mg four times daily for 14 days
Explanation: ***Stop co-amoxiclav, start oral vancomycin 125mg four times daily for 10 days***- This patient has a first episode of **non-severe Clostridioides difficile infection (CDI)**, as evidenced by a white cell count (WCC) < 15 x 10⁹/L and no significant creatinine rise.- Current guidelines recommend **oral vancomycin 125mg QID for 10 days** as the first-line treatment for an initial episode of non-severe CDI, along with **discontinuation of the precipitating antibiotic** (co-amoxiclav).*Continue co-amoxiclav, add oral metronidazole 400mg three times daily for 10 days*- **Metronidazole** is less effective than oral vancomycin for CDI and is no longer considered first-line for non-severe cases in many guidelines.- **Continuing the inciting antibiotic**, co-amoxiclav, will worsen the CDI and potentially lead to treatment failure and prolonged symptoms.*Stop co-amoxiclav, start oral fidaxomicin 200mg twice daily for 10 days*- **Fidaxomicin** is highly effective but is typically reserved for **recurrent CDI** or patients at very high risk of recurrence due to its higher cost.- While a valid option, **oral vancomycin** remains the standard first-line and more cost-effective choice for a first episode of non-severe CDI in most clinical protocols.*Stop co-amoxiclav, start intravenous metronidazole 500mg three times daily for 10 days*- **Intravenous metronidazole** is ineffective for typical CDI because it does not achieve sufficient therapeutic concentrations within the colonic lumen, where the infection is located.- This route is only indicated for **fulminant or severe CDI** when oral intake is compromised (e.g., ileus) or as an adjunct to oral therapy for systemic effects.*Stop co-amoxiclav, start oral vancomycin 500mg four times daily for 14 days*- A **higher dose of oral vancomycin** (500mg) is reserved for **severe or complicated CDI**, sometimes in combination with other agents or for recurrent disease.- For non-severe CDI, the standard **125mg dose** is equally effective, safer, and recommended for a 10-day duration.
